Zobrazeno 1 - 10
of 20
pro vyhledávání: '"P. M. Polasek"'
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-4 (2024)
Abstract Background Phase 1 clinical trials involve rigorous safety monitoring to identify any adverse effects of investigational treatments. There is growing evidence that healthy volunteers recruited in these studies may differ with respect to pers
Externí odkaz:
https://doaj.org/article/4581233f44644036845d84289a9e73a9
Autor:
Sam Mostafa, Reza Rafizadeh, Thomas M. Polasek, Chad A. Bousman, Amin Rostami‐Hodjegan, Robert Stowe, Prescilla Carrion, Leslie J. Sheffield, Carl M. J. Kirkpatrick
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 424-436 (2024)
Abstract Model‐informed precision dosing using virtual twins (MIPD‐VTs) is an emerging strategy to predict target drug concentrations in clinical practice. Using a high virtualization MIPD‐VT approach (Simcyp version 21), we predicted the stead
Externí odkaz:
https://doaj.org/article/7d8f3b86d1004aa6a7d17a743b344511
Autor:
Kiflu G. Tesfamicael, Lijun Zhao, Rubén Fernández-Rodríguez, David L. Adelson, Michael Musker, Thomas M. Polasek, Martin David Lewis
Publikováno v:
Frontiers in Psychiatry, Vol 15 (2024)
AimTo determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis.MethodsA comprehensive systematic search was conducted on PsycINFO, P
Externí odkaz:
https://doaj.org/article/d96a05ae63d949b6935510e20624f844
Autor:
Richard T. Kenney, John K. Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P. Chawla, Thomas M. Polasek, Jason Lickliter, Philip J. Ryan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 s
Externí odkaz:
https://doaj.org/article/9baead1eb8e549ccaed6f20a613f9c70
Autor:
Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Jane Gunn, Timothy F. Chen, Thomas M. Polasek, Elise Dettmann, Rachel Brooks, Michelle King, Luke Spencer, Pavithran Alphonse, Shakira Milton, Georgia Ramsay, Zoe Siviour, Jamie Liew, Philip Ly, Matthew Thoenig, Raushaan Seychell, Floriana La Rocca, Luke B. Hesson, Nydia Mejias, Terri Sivertsen, Melanie Anne Galea, Chad Bousman, Jon Emery
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-18 (2023)
Abstract Background The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx
Externí odkaz:
https://doaj.org/article/55d8406932cd4f07b01ea962249ddd20
Autor:
Thomas M. Polasek
Publikováno v:
Frontiers in Digital Health, Vol 5 (2023)
Healthcare is increasingly fragmented, resulting in escalating costs, patient dissatisfaction, and sometimes adverse clinical outcomes. Strategies to decrease healthcare fragmentation are therefore attractive from payer and patient perspectives. In t
Externí odkaz:
https://doaj.org/article/39afb08232f349aa90100d0f4cfb4de0
Autor:
Sam Mostafa, Thomas M. Polasek, Chad Bousman, Amin Rostami‐Hodjegan, Leslie J. Sheffield, Ian Everall, Christos Pantelis, Carl M. J. Kirkpatrick
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 168-179 (2023)
Abstract Studies that focus on individual covariates, while ignoring their interactions, may not be adequate for model‐informed precision dosing (MIPD) in any given patient. Genetic variations that influence protein synthesis should be studied in c
Externí odkaz:
https://doaj.org/article/730d77bd6c7e4a90974bd9c7af6e6367
Autor:
Thomas M. Polasek
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Unexpected poor efficacy and intolerable adverse effects are medication-related problems that may result from genetic variation in genes encoding key proteins involved in pharmacokinetics or pharmacodynamics. Pharmacogenomic (PGx) testing can be used
Externí odkaz:
https://doaj.org/article/2373c3a6e4ba4a0ab0f3962deb2e6138
Publikováno v:
Frontiers in Psychiatry, Vol 12 (2021)
Introduction: Polypharmacy and genetic variants that strongly influence medication response (pharmacogenomics, PGx) are two well-described risk factors for adverse drug reactions. Complexities arise in interpreting PGx results in the presence of co-a
Externí odkaz:
https://doaj.org/article/6e97562e804145b2bddd2a64cbb86812
Publikováno v:
F1000Research, Vol 10 (2021)
Background: Genetic testing in clinical trials introduces several ethical and logistical issues to discuss with potential participants when taking informed consent. The aim of this study was to explore the attitudes of healthy volunteers in phase 1 s
Externí odkaz:
https://doaj.org/article/dd26bed9e01247e9aa15ccf59f01778d